Stock OCGN OCUGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Ocugen, Inc.

Equities

OCGN

US67577C1053

Real-time Estimate Cboe BZX
Other stock markets
 03:19:57 2024-05-17 pm EDT 		5-day change 1st Jan Change
1.895 USD -4.29% Intraday chart for Ocugen, Inc. +18.55% +227.83%
May. 15 Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study MT
May. 15 Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST?A Modifier Gene Therapy CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study
MT
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST?A Modifier Gene Therapy
CI
Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024
CI
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration
MT
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy
CI
Ocugen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for Ocu400?Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
CI
Ocugen Gets FDA Clearance for IND Amendment for OCU400
DJ
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial
CI
Sector Update: Health Care Stocks Rise Late Afternoon
MT
Sector Update: Health Care Stocks Rise Friday Afternoon
MT
Ocugen Says Data, Safety Monitoring Board Issues 'Positive' Review of Eye Disease Treatment -- Shares Rise
MT
Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy
CI
Sector Update: Health Care Stocks Slipping in Afternoon Trading
MT
Ocugen to Restate Financial Statements; Shares Tumble
MT
Ocugen Provides Business Update
CI
North American Morning Briefing : Stocks Seen -2-
DJ
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410st?A Modifier Gene Therapy?In Gardian Study for Stargardt Disease
CI
Sector Update: Health Care Stocks Steady Premarket Monday
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCGN Stock
  4. News Ocugen, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW